Radiation-activated secretory proteins of Scgb1a1 + club cells increase the efficacy of immune checkpoint blockade in lung cancer.
Yi BanGeoffrey J MarkowitzYue ZouDivya RamchandaniJeffrey KraynakJianting ShengSharrell B LeeStephen T C WongNasser K AltorkiDingcheng GaoVivek MittalPublished in: Nature cancer (2021)
Radiation therapy (RT) in combination with immune checkpoint inhibitor (ICI) represents a promising regimen for non-small cell lung cancer (NSCLC), however, the underlying mechanisms are poorly characterized. We identified a specific dose of RT that conferred tumor regression and improved survival in NSCLC models when combined with ICI. The immune-modulating functions of RT was ascribed to activated lung-resident Scgb1a1+ club cells. Importantly, mice with club cell-specific knockout of synaptosome-associated protein 23 failed to benefit from the combination treatment, indicating a pivotal role of club cell secretome. We identified 8 club cells secretory proteins, which inhibited immunosuppressive myeloid cells, reduced pro-tumor inflammation, and enhanced anti-tumor immunity. Notably, CC10, a member of club cell secretome was increased in plasma of NSCLC patients responding to the combination therapy. By revealing an immune-regulatory role of club cells, our studies have the potential to guide future clinical trials of ICI in NSCLC.
Keyphrases
- induced apoptosis
- cell cycle arrest
- small cell lung cancer
- clinical trial
- radiation therapy
- combination therapy
- oxidative stress
- endoplasmic reticulum stress
- single cell
- end stage renal disease
- advanced non small cell lung cancer
- type diabetes
- squamous cell carcinoma
- dendritic cells
- bone marrow
- climate change
- peritoneal dialysis
- pi k akt
- current status
- prognostic factors
- insulin resistance
- free survival
- epidermal growth factor receptor